Fig. 3.

Patients achieving vIGA-AD 0/1^a from baseline to week 112. Data are presented using the observed cases approach. All patients received concomitant topical corticosteroids from baseline to week 16. After week 16, the use of concomitant topical corticosteroids was no longer required and was administered per investigator discretion. ^aPatients achieving vIGA-AD 0/1 with at least two grades of reduction from baseline. PBO placebo, UPA upadacitinib, vIGA-AD 0/1 validated Investigator Global Assessment for AD score of clear or almost clear